The first patients have been enrolled in two clinical trials of the experimental drug neridronate. The trials are part of the company’s Phase 3 program to evaluate the effects of neridronate on the treatment of complex regional pain syndrome (CRPS). The full article can be read here, at PR Newswire.

CRPS is a condition associated with debilitating and persistent pain. It is estimated that about one in every 3,800 people in the UK is affected by CRPS, approximately 75% of who are women. It is usually triggered by an injury or surgery and can affect a localised area of the body or spread. Areas that are affected often become hypersensitive, and intense pain may be caused by even light touches or temperature changes. These areas might also show swelling, colour change, temperature change, or stiffness. Over time the condition may improve, but CRPS is poorly understood and the treatment options are currently very limited.

The potential new treatment for CRPS, neridronate, is being tested in two Phase 3 clinical trials, known as KF7013-02 and KF703-04. These trials will evaluate the efficacy and safety of the drug in a total of 360 patients with CRPS by evaluating its effects on symptoms such as pain, swelling, and allodynia amongst others.  The effects of the drug will be compared to those of a placebo over twelve weeks.

Neridronate has previously been granted Fast Track and Breakthrough Therapy designations by the US Food and Drug Administration, which will allow closer contact between the developers and the FDA, leading to a faster development process.

What are your thoughts on this clinical trial? Share your stories, thoughts, and hopes with the Patient Worthy community!